Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus

Neurodegenerative Diseases

Volumn 13, Issue 4, 2014, Pages 237-245

  Rinne, Juha O ^a   Frantzen, Janek ^b   Leinonen, Ville ^c,d   Lonnrot, Kimmo ^e   Laakso, Aki ^f   Virtanen, Kirsi A ^a   Solin, Olof ^a   Kotkansalo, Anna ^b   Koivisto, Anne ^d,g   Sajanti, Juha ^e   Karppinen, Atte ^f   Lehto, Hanna ^f   Rummukainen, Jaana ^c   Buckley, Chris ⁱ   Smith, Adrian ^j   Jones, Paul A ^j   Sherwin, Paul ^l   Farrar, Gill ^k   McLain, Richard ^m   Kailajarvi, Marita ^h   Grachev, Igor D ^l   more..

^a TURKU PET CENTRE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g Department of Neurology ^*  (Finland)

^h GE Healthcare Finland Oy   (Finland)

ⁱ Imaging Technology   (United Kingdom)

^j Discovery Biology   (United Kingdom)

^k GE HEALTHCARE   (United Kingdom)

^l GE HEALTHCARE   (United States)

^m PFP Statistical Consulting LLC   (United States)

more..

Author keywords

Amyloid ; Cortical brain biopsy; Flutemetamol; Histopathology; Normal pressure hydrocephalus; Positron emission tomography; Ventriculoperitoneal shunting

Indexed keywords

AMYLOID BETA PROTEIN; FLUTEMETAMOL F 18; ANILINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; FLUTEMETAMOL; MONOCLONAL ANTIBODY;

ADULT; AGED; AMYLOID NEUROPATHY; AMYLOID PLAQUE; ARTICLE; BRAIN BIOPSY; BRAIN VENTRICLE PERITONEUM SHUNT; CEREBELLUM CORTEX; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROIMAGING; NORMOTENSIVE HYDROCEPHALUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ALZHEIMER DISEASE; CLINICAL TRIAL; DIAGNOSTIC USE; PATHOLOGY; SCINTISCANNING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; FRONTAL CORTEX; MOTION SICKNESS; NAUSEA; PET SCANNER; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BENZOTHIAZOLES; FEMALE; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 84899910077     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000355256     Document Type: Article

References (25)

1. Vallet PG, Guntern R, Hof PR, et al: A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol 1992; 83: 170-178.
2. Cooper JH: An evaluation of current methods for the diagnostic histochemistry of amyloid. J Clin Pathol 1969; 22: 410-413.
3. Ikonomovic MD, Klunk WE, Abrahamson EE, et al: Post-mortem correlates of in vivo PiBPET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645.
4. Nelissen N, Van LK, Thurfjell L, et al: Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009; 50: 1251-1259.
5. Edison P, Hinz R, Brooks DJ: Technical aspects of amyloid imaging for Alzheimer's disease. Alzheimers Res Ther 2011; 3: 25.
6. Leinonen V, Koivisto AM, Savolainen S, et al: Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol 2010; 68: 446-453.
7. Golomb J, Wisoff J, Miller DC, et al: Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 2000; 68: 778-781.
8. Hamilton R, Patel S, Lee EB, et al: Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol 2010; 68: 535-540.
9. Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, Smith A, McLain R, Sherwin PF, Farrar G, Kailajärvi M, Grachev ID: [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012; 124: 833-845.
10. Raji CA, Becker JT, Tsopelas ND, et al: Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods 2008; 172: 277-282.
11. Jack CR Jr, Lowe VJ, Senjem ML, et al: 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-680.
12. Rinne JO, Brooks DJ, Rossor MN, et al: 11CPiB PET assessment of change in fibrillar amyloidbeta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascendingdose study. Lancet Neurol 2010; 9: 363-372.
13. Mirra SS, Heyman A, McKeel D, et al: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
14. Seppälä TT, Nerg O, Koivisto AM, et al: CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012; 78: 1568-1575.
15. Spillantini MG, Goedert M, Jakes R, Klug A: Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci USA 1990; 87: 3947-3951.
16. Vandenberghe R, Van LK, Ivanoiu A, et al: 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319-329.
17. Leinonen V, Alafuzoff I, Aalto S, et al: Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-1309.
18. Wolk DA, Grachev ID, Buckley C, et al: Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68: 1398-1403.
19. Clark CM, Schneider JA, Bedell BJ, et al: Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275-283.
20. Jack CR Jr, Lowe VJ, Weigand SD, et al: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
21. Koivunen J, Scheinin N, Virta JR, et al: Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76: 1085-1090.
22. Rowe CC, Ng S, Ackermann U, et al: Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
23. Braak H, Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357.
24. Thal DR, Rub U, Orantes M, et al: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
25. Koivisto AM, Alafuzoff I, Savolainen S, et al: Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus. Neurosurgery 2013; 72: 1-8.